Compare Stocks → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATXINASDAQ:MTCRNASDAQ:MTPOTCMKTS:NEVPFOTCMKTS:QBIO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$4.40+4.8%$10.06$4.04▼$93.75$2.60M-0.0981,741 shs205,509 shsMTCRMetacrine$0.58$0.57$0.30▼$0.59$24.75M-0.73225,834 shs83,889 shsMTPBiodexa Pharmaceuticals$1.95$0.29▼$5.25$6.18M2.2957,354 shs164,300 shsNEVPFAbliva AB (publ)$0.01$0.01$0.01▼$0.02N/A0.54N/AN/AQBIOQ BioMed$0.00$0.00$0.00▼$0.02$73K1.8243,668 shs20,650 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics+4.76%-7.56%-61.78%-58.33%-94.22%MTCRMetacrine0.00%0.00%0.00%0.00%+1.11%MTPBiodexa Pharmaceuticals0.00%0.00%0.00%0.00%0.00%NEVPFAbliva AB (publ)0.00%0.00%0.00%-50.00%0.00%QBIOQ BioMed0.00%+150.00%+66.67%-37.50%-95.45%348 million Americans lives to END as we know it? (Ad)348 million American lives are about to change FOREVER.... Because thanks to one shocking A.I. development I'm revealing for the first time today...To see my free research, simply click here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATXIAvenue Therapeutics0.7801 of 5 stars0.04.00.04.62.20.00.0MTCRMetacrineN/AN/AN/AN/AN/AN/AN/AN/AMTPBiodexa PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AQBIOQ BioMedN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXIAvenue Therapeutics3.00BuyN/AN/AMTCRMetacrineN/AN/AN/AN/AMTPBiodexa PharmaceuticalsN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/AQBIOQ BioMedN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/AMTCRMetacrineN/AN/AN/AN/A$1.36 per shareN/AMTPBiodexa Pharmaceuticals$800K0.00N/AN/A$5.67 per share0.00NEVPFAbliva AB (publ)N/AN/AN/AN/A$0.04 per shareN/AQBIOQ BioMed$280K0.26N/AN/A($0.11) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXIAvenue Therapeutics-$10.38M-$95.49N/A∞N/AN/AN/A-335.11%5/10/2024 (Estimated)MTCRMetacrine-$62.21M-$1.03N/A∞N/AN/A-84.88%-59.33%N/AMTPBiodexa Pharmaceuticals-$7.51MN/A0.00N/AN/AN/AN/AN/AN/ANEVPFAbliva AB (publ)-$8.45MN/A0.00∞N/AN/A-63.75%-57.93%N/AQBIOQ BioMed-$2.05M-$0.03N/A∞N/AN/AN/AN/A5/26/2024 (Estimated)Latest ATXI, MTP, MTCR, QBIO, and NEVPF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023ATXIAvenue TherapeuticsN/A$42.00+$42.00$0.56N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXIAvenue TherapeuticsN/AN/AN/AN/AN/AMTCRMetacrineN/AN/AN/AN/AN/AMTPBiodexa PharmaceuticalsN/AN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/AN/AQBIOQ BioMedN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXIAvenue TherapeuticsN/A1.551.55MTCRMetacrine0.3412.1512.15MTPBiodexa PharmaceuticalsN/AN/AN/ANEVPFAbliva AB (publ)N/A6.606.60QBIOQ BioMedN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXIAvenue Therapeutics17.34%MTCRMetacrine37.72%MTPBiodexa Pharmaceuticals4.21%NEVPFAbliva AB (publ)N/AQBIOQ BioMedN/AInsider OwnershipCompanyInsider OwnershipATXIAvenue Therapeutics1.80%MTCRMetacrine13.80%MTPBiodexa Pharmaceuticals0.34%NEVPFAbliva AB (publ)N/AQBIOQ BioMed28.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATXIAvenue Therapeutics3590,000578,000Not OptionableMTCRMetacrine1042.57 million36.70 millionNot OptionableMTPBiodexa Pharmaceuticals1821.67 million21.60 millionNot OptionableNEVPFAbliva AB (publ)8N/AN/ANot OptionableQBIOQ BioMed3145.10 million104.18 millionNot OptionableATXI, MTP, MTCR, QBIO, and NEVPF HeadlinesSourceHeadlineE&Q Master Cordless Gutta Percha Obturator from Meta BioMednews-medical.net - March 24 at 4:19 AMClearside Biomedical Q4 2023 Earnings Previewmsn.com - March 11 at 7:34 PMQ BioMed Stock (OTC:QBIO) Dividends: History, Yield and Datesbenzinga.com - February 24 at 3:23 AMBiogen Inc. (BIIB) Lags Q4 Earnings and Revenue Estimatesmsn.com - February 13 at 1:26 PMBioxyne’s Q2 FY24 revenue surpasses $2.5m on Aussie medicinal cannabis growthmsn.com - January 28 at 11:09 PMQ BioMed Inc QBIOmorningstar.com - November 16 at 1:23 PMBiomedical Sciences PhD Programuwyo.edu - November 13 at 2:32 PMQ&A: How generative AI could help accelerate biomedical researchphys.org - November 6 at 8:46 AMQBIO Q BioMed Inc.seekingalpha.com - August 18 at 4:51 AMQ BioMed’s chemotherapeutic Uttroside B gets US patent and notice of allowance in Europepharmabiz.com - April 17 at 9:36 AMQ BioMed receives US patent and notice of allowance in Europe for Uttroside B; seeks ways to boost shareholder valueproactiveinvestors.com - April 14 at 10:53 AMQ BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europefinance.yahoo.com - April 14 at 10:53 AMQ BioMed Stock (OTC:QBIO), Quotes and News Summarybenzinga.com - March 3 at 4:23 PMQ BioMed gets notice of allowable US patent for liver cancer treatment Uttroside Bproactiveinvestors.com - February 10 at 3:27 PMQ BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Officefinance.yahoo.com - February 10 at 8:27 AMShort Volatility Alert: Q Biomed Incbenzinga.com - January 12 at 2:36 PMQ BioMed Inc. (QBIO)finance.yahoo.com - January 1 at 5:15 PMQ BioMed boosted by multi-million dollar asset as it converts long-term royalty into equity stake in Mannin Researchproactiveinvestors.com - November 14 at 2:22 PMQ BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC.finance.yahoo.com - November 14 at 9:20 AMQ BIOMED PROVIDES SHAREHOLDER UPDATEprnewswire.com - October 11 at 8:38 AMQ Biomed announces patent for groundbreaking GDF15 biomarker for glaucoma detection and treatmentproactiveinvestors.com - September 27 at 1:02 PMQ BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKERfinance.yahoo.com - September 27 at 1:02 PMTraders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc.finance.yahoo.com - August 25 at 10:16 AMWhat to Expect at BIOMEDevice Bostonmddionline.com - August 10 at 3:59 PMNew MarketBeat Followers Over TimeCompany DescriptionsAvenue TherapeuticsNASDAQ:ATXIAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.MetacrineNASDAQ:MTCRMetacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Biodexa PharmaceuticalsNASDAQ:MTPBiodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Abliva AB (publ)OTCMKTS:NEVPFAbliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.Q BioMedOTCMKTS:QBIOQ BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.